Ageing drug discovery biotech sees exciting earlyin vivodata for lead compound

Download the full case study below

Five Alarm Bio is a UK drug discovery startup focussing on the underlying mechanisms of ageing to develop therapeutics for age-related disease. 

They found their lead compound slowed cell senescence in in vitro studies of primary human diploid fibroblasts. But for the next stage, it was important to show that the compound slowed ageing in a whole organism.

C. elegans was the perfect solution, where major breakthroughs have occurred by identifying mutants and other interventions that increase lifespan. 

Instead of the one data point-per animal approach of lifespan, Magnitude Biosciences’ unique automated Healthspan technology generates multiple mobility endpoints to truly understand whether compounds slow ageing. 

Five Alarm Bio looked to work with a reputable CRO like Magnitude Biosciences, to be confident the study would be complete to a high standard.

FAB001 showed no acute, developmental or reproductive toxicity.

Magnitude Biosciences found that there was no detectable reproductive or developmental toxicity caused by the compound even at 5 mM, the highest concentration tested, 

FAB001 slowed C. elegans ageing in the Magnitude Biosciences Healthspan assay.

The fraction of worms moving stayed higher after day 2 of adulthood, the point when ageing starts to have an effect.

FAB001 was one of the strongest compounds seen in Magnitude Biosciences’ extensive experience of testing compounds for efficacy to slowing ageing. 

Five Alarm Bio CSO William Bains commented “ We are really enthusiastic about doing more work with Magnitude Biosciences in the future”.

See the details on what methodologies were used to generate this data. Download the full case study here: https://magnitudebiosciences.com/ageing-drug-discovery-case-study-5alarmbio-magnitude-biosciences/